drugset
drugset / Trial / NCT00659347

Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder

NCT00659347 ↗

Phase 2 Terminated 200 enrolled DOV Pharmaceutical, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objectives of this placebo-controlled trial are to evaluate effectiveness and safety of DOV 21,947 at two oral dose levels.

Timeline

Start
2008-03
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator AMITIFADINE Small molecule 50 mg Oral

Indications

major depressive disorder